Emergent BioSolutions Acquires Portfolio of Broad Spectrum Antibiotics

We advised Emergent BioSolutions (NYSE:EBS) on the government contract related aspects of its acquisition of assets related to a contract with the Defense Threat Reduction Agency. Emergent BioSolutions purchased the EV-035 series of molecules, a portfolio of broad spectrum antibiotics that may fight bioterrorism agents, from Evolva Holdings SA (SIX:EVE).

Emergent BioSolutions (NYSE:EBS) is a global specialty biopharmaceutical company.

You Also May Be Interested In:

  • Representing the independent Special Committee of Strategic Storage Growth Trust, Inc. (SSGT), in its definitive agreement to merge with Strategic Storage Trust II, Inc., (SST II) in an all-cash merger valued at $340 million expected to close during the first quarter of 2019, subject to customary closing conditions, including the approval of SSGT’s stockholders

    We are representing the independent Special Committee of Strategic Storage Growth Trust, Inc. (SSGT), in its definitive agreement to merge...
    Client Type: Private Company
  • Represented Wright Medical Group in its acquisition of Cartiva, Inc.

    We served as lead counsel to Wright Medical Group N.V. (Nasdaq: WMGI) in the acquisition of Cartiva, Inc., a privately-held...
    Client Type: Public Company
  • We represented NN, Inc. (Nasdaq: NNBR) in its public offering of 14,375,000 shares of common stock, which was composed of...
    Client Type: Public Company